Article
Comparison of epidermal growth factor receptor mutation detection turnaround times and concordance among real-time polymerase chain reaction, high-throughput next-generation sequencing and the Biocartis Idylla™ platforms in non-small cell lung carcinomas.
Pathology, research and practice - 1 Apr 2021
Sharma Shivani, Satapathy Abhishek, Aggarwal Aditi, Dewan Aditi, Jain Ekta, Katara Rahul, Kumar Vipin, Pal Rajan, Pandey Santosh, Naidu Machita M, Kini Lata, Pradhan Dinesh, Mohanty Sambit K
Abstract excerpt
OBJECTIVES: Activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor (EGFR) gene of non-small cell lung carcinomas (NSCLC) can be targeted by the tyrosine kinase inhibitors. A number of molecular diagnostic platforms are used to detect actionable targets in the exon(s) 18, 19, 20, and 21 of the EGFR gene. The Idylla™ system (Biocartis, Mechelen, Belgium) is a relatively novel...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.